Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients ; volume:15 ; number:1 ; day:1 ; month:4 ; year:2014 ; pages:1-10 ; date:12.2014
BMC musculoskeletal disorders ; 15, Heft 1 (1.4.2014), 1-10, 12.2014
- Urheber
-
Pappas, Dimitrios A.
- Beteiligte Personen und Organisationen
-
Kremer, Joel M.
Reed, George
Greenberg, Jeffrey D.
Curtis, Jeffrey R.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2474-15-113
- URN
-
urn:nbn:de:1111-2016043029277
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pappas, Dimitrios A.
- Kremer, Joel M.
- Reed, George
- Greenberg, Jeffrey D.
- Curtis, Jeffrey R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Biologic agents in juvenile spondyloarthropathies
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study
Dopaminergic Agents in Rheumatoid Arthritis
Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Biologic agents in juvenile spondyloarthropathies
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study
Dopaminergic Agents in Rheumatoid Arthritis
Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis
Biologic monotherapy in the biologic naïve patient with rheumatoid arthritis (RA): results from an observational study
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Biologic agents in juvenile spondyloarthropathies
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study
Administration costs of intravenous biologic drugs for rheumatoid arthritis
Use of biologic agents and methotrexate improves renal manifestation and outcome in patients with rheumatoid arthritis: a retrospective analysis
Do biologic therapies reduce aortic inflammation in rheumatoid arthritis patients?
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study
Dopaminergic Agents in Rheumatoid Arthritis